Sight Diagnostics Overview
Sight Diagnostics uses advanced computer-vision and machine-learning technology in the field of blood diagnostics. The companys initial product, the Parasight platform, is a highly accurate, easy-to-use device for diagnosing malaria. Sight Diagnostics is also applying its technology to the complete blood count (CBC) market, developing a point-of-care CBC platform that will provide a five-point differential blood count for use in doctors offices and emergency medical centers. Beyond its malaria and CBC platforms, the companys computer-vision technology has the potential to unlock advanced diagnostic approaches to numerous additional diseases and provide patients with accurate and inexpensive testing. In December 2019, the company received FDA 510(k) clearance for its OLO analyzer, a device that performs blood tests and provides lab-grade results in minutes. Tests include the complete blood count (CBC) panel, which comprises the most common and useful tests conducted by medical professionals.
Cumulative Funding Raised Over Time ($)
$6.0MApr 2014
$9.2MAug 2011
$25.0MAug 2016
$52.8MFeb 2019
$123.8MJul 2020
Latest News
growth-negative
המייסד עזב, החברה התכווצה והפיתוח המרכזי נזנח: מה קורה ב-Sight Diagnostics
Sight Diagnostics, a Tel Aviv-based medical device company founded in 2011, developed a rapid blood count device and attracted significant investor interest during the rise of Theranos. However, after the market shifted and development phases concluded, the company realized that blood counting was a solved problem. Following the departure of its founder and extensive layoffs, Sight Diagnostics is attempting to reinvent itself. The company, which once employed 250 people, now has 70 employees, with plans to reduce this number to 40 by the end of the year. The company has raised approximately $124 million since its inception.
LayoffsManagement Changes
growth-negative
חברת המכשור הרפואי סייט דיאגנוסטיקה מפטרת 40 עובדים - 30% מכוח האדם שלה | כלכליסט
Sight Diagnostics, an Israeli medical device company that developed a device for rapid blood count, has laid off 30% of its employees. This is the second significant round of layoffs for the company after a major reorganization in 2022 that included employee layoffs and significant changes in company management. According to LinkedIn, the company employs about 130 people, so the number of layoffs is about 40. The company was founded in 2011 and has raised about $124 million to date.
LayoffsManagement Changes
growth-positive
Much-Needed Breakthrough Medical Technology Deployed for the First Time in Trinidad and Tobago - CaribMagPlus
Sight Diagnostics has installed its first portable hematology analytical instrument, the OLO, in the Caribbean. The device will provide near-immediate Complete Blood Count (CBC) results to patients in Trinidad and Tobago, particularly in critical care, oncology, and pediatrics. The OLO will replace bulky Flow Cytometers in low-volume and critical-need point-of-care testing sites. The device is portable, cost-effective, and does not compromise the accuracy of blood tests. The product will be sold through Sapphire Export Group and JT Rapid Diagnostics, Ltd in the CARICOM region and Trinidad and Tobago respectively.
CustomersPartners
growth-positive
Blood is thicker than water. Israeli tech is utilizing that
The article discusses the innovative efforts of several Israeli MedTech startups in the field of blood analytics and diagnostics. PixCell, which was acquired by Soulbrain Holdings in 2021, has developed a device for efficient cell analytics. RedC Biotech has created a universal red blood cell transfusion product, while Improdia has developed a simple way to monitor inflammation levels. Sight Diagnostics has developed a blood analyzer that performs a Complete Blood Count in minutes, and EFA has developed a mobile diagnostic system. OrSense focuses on non-invasive monitoring technologies, and PatenSee has developed a surveillance system for the early detection of vascular stenosis.
CustomersInvestmentAcquisition
growth-positive
Sight Diagnostics® and Inter Medico Announce the Health Canada Approval of Sight OLO for Point-of-Care Testing
Sight Diagnostics has received Health Canada approval to provide Sight OLO analyzers for point-of-care settings. This approval allows the company to bring 5-part differential Complete Blood Count (CBC) testing to emergency departments, hospitals, and other decentralized settings across Canada. The Sight OLO analyzer requires only 2 drops of blood and delivers results in minutes. The approval expands Sights market reach in Canada and allows clinicians in various healthcare settings to make fast and accurate treatment decisions. The companys distribution partner, Inter Medico, will facilitate the distribution of Sight OLO analyzers in Canada. The approval is expected to have a positive impact on the companys growth.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $123.8M |
| Last funding | $71M |
| Stage | Mature |
| Rounds | 5 |
| Investors | 13 |
Team Members
2
Employees: 51-200
Web & Social Links
| Website | sightdx.com/en |
| Careers | Careers page |
Locations
Derech Menachem Begin 23, Tel Aviv-Yafo, Tel Aviv District, Israel
Photos & Videos
3 item(s)
Sight Diagnostics Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportDigital Medical DiagnosticsMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersLaboratoriesCore Technology
Artificial IntelligenceComputer VisionMachine LearningTags (22)
blood-testmedical-devicesdiagnosticsreal-timecomputer-visioninfectious-diseasehematologybioinformaticsartificial-intelligencemedical-technologiespediatricsoncologydata-analyticsinfectionhospitalsdigital-healthcaremachine-learningdetectiondoctorsimage-processingclinicslaboratoriesGeographic Markets
United Arab EmiratesNigeriaEuropeColombiaIndiaUnited KingdomUnited StatesItalyAfricaGhanaKenyaSight Diagnostics Financials
$123.8M
Total funding
Undisclosed
Capital raised
$71M
Last funding
Mature
Funding stage
5
Total rounds
13
Investors
Cumulative Funding Raised Over Time ($)
$6.0MApr 2014
$9.2MAug 2011
$25.0MAug 2016
$52.8MFeb 2019
$123.8MJul 2020
Private Equity Funding
D Round
Jul 2020
$71M
Koch Disruptive Technologies, Longliv Ventures, OurCrowd
C Round
Feb 2019
$27.8M
Jack Nicklaus II, GEOC, Longliv Ventures, New Alliance Capital, OurCrowd, Steven Esrick
B Round
Aug 2016
$15.8M
OurCrowd, Qure Ventures, GEOC, New Alliance Capital, Formed
A Round
Apr 2014
$6M
OurCrowd (Lead)
,
Innovation Endeavors, Clal Biotechnology Industries (CBI), Moshe Yanai, Emery Capital, Qure Ventures
Seed
Aug 2011
$3.2M
Moshe Yanai
Sight Diagnostics Lifecycle
Cumulative Funding Raised Over Time
$6.0MApr 2014
$9.2MAug 2011
$25.0MAug 2016
$52.8MFeb 2019
$123.8MJul 2020
All Events
D Round
Jul 2020
$71M
Koch Disruptive Technologies, Longliv Ventures, OurCrowd
C Round
Feb 2019
$27.8M
Jack Nicklaus II, GEOC, Longliv Ventures, New Alliance Capital, OurCrowd, Steven Esrick
B Round
Aug 2016
$15.8M
OurCrowd, Qure Ventures, GEOC, New Alliance Capital, Formed
A Round
Apr 2014
$6M
OurCrowd (Lead)
,
Innovation Endeavors, Clal Biotechnology Industries (CBI), Moshe Yanai, Emery Capital, Qure Ventures
Seed
Aug 2011
$3.2M
Moshe Yanai
Sight Diagnostics News
25 articles
growth-negative
המייסד עזב, החברה התכווצה והפיתוח המרכזי נזנח: מה קורה ב-Sight Diagnostics
Sight Diagnostics, a Tel Aviv-based medical device company founded in 2011, developed a rapid blood count device and attracted significant investor interest during the rise of Theranos. However, after the market shifted and development phases concluded, the company realized that blood counting was a solved problem. Following the departure of its founder and extensive layoffs, Sight Diagnostics is attempting to reinvent itself. The company, which once employed 250 people, now has 70 employees, with plans to reduce this number to 40 by the end of the year. The company has raised approximately $124 million since its inception.
LayoffsManagement Changes
growth-negative
חברת המכשור הרפואי סייט דיאגנוסטיקה מפטרת 40 עובדים - 30% מכוח האדם שלה | כלכליסט
Sight Diagnostics, an Israeli medical device company that developed a device for rapid blood count, has laid off 30% of its employees. This is the second significant round of layoffs for the company after a major reorganization in 2022 that included employee layoffs and significant changes in company management. According to LinkedIn, the company employs about 130 people, so the number of layoffs is about 40. The company was founded in 2011 and has raised about $124 million to date.
LayoffsManagement Changes
growth-positive
Much-Needed Breakthrough Medical Technology Deployed for the First Time in Trinidad and Tobago - CaribMagPlus
Sight Diagnostics has installed its first portable hematology analytical instrument, the OLO, in the Caribbean. The device will provide near-immediate Complete Blood Count (CBC) results to patients in Trinidad and Tobago, particularly in critical care, oncology, and pediatrics. The OLO will replace bulky Flow Cytometers in low-volume and critical-need point-of-care testing sites. The device is portable, cost-effective, and does not compromise the accuracy of blood tests. The product will be sold through Sapphire Export Group and JT Rapid Diagnostics, Ltd in the CARICOM region and Trinidad and Tobago respectively.
CustomersPartners
growth-positive
Blood is thicker than water. Israeli tech is utilizing that
The article discusses the innovative efforts of several Israeli MedTech startups in the field of blood analytics and diagnostics. PixCell, which was acquired by Soulbrain Holdings in 2021, has developed a device for efficient cell analytics. RedC Biotech has created a universal red blood cell transfusion product, while Improdia has developed a simple way to monitor inflammation levels. Sight Diagnostics has developed a blood analyzer that performs a Complete Blood Count in minutes, and EFA has developed a mobile diagnostic system. OrSense focuses on non-invasive monitoring technologies, and PatenSee has developed a surveillance system for the early detection of vascular stenosis.
CustomersInvestmentAcquisition
growth-positive
Sight Diagnostics® and Inter Medico Announce the Health Canada Approval of Sight OLO for Point-of-Care Testing
Sight Diagnostics has received Health Canada approval to provide Sight OLO analyzers for point-of-care settings. This approval allows the company to bring 5-part differential Complete Blood Count (CBC) testing to emergency departments, hospitals, and other decentralized settings across Canada. The Sight OLO analyzer requires only 2 drops of blood and delivers results in minutes. The approval expands Sights market reach in Canada and allows clinicians in various healthcare settings to make fast and accurate treatment decisions. The companys distribution partner, Inter Medico, will facilitate the distribution of Sight OLO analyzers in Canada. The approval is expected to have a positive impact on the companys growth.
CustomersPartners
growth-positive
Israel's Sight Diagnostics' Sight OLO deployed at Oxford University's John Radcliffe Hospital
Sight Diagnostics has deployed its Sight OLO solution at the John Radcliffe Hospital, allowing patients to have quick Full Blood Count (FBC) testing as part of a rapid AI triage system for Covid-19. The deployment is a collaboration with Oxford University and their CURIAL analysis program. The CURIAL algorithm, developed by Oxford University, can rule out the possibility of Covid-19 within patients in the first hour. Sight OLO can reduce the time for FBC results to just 30 minutes. Sight Diagnostics aims to support other health institutions by providing fast and accurate FBC testing through OLO. The companys analyzer, Sight OLO, can perform a Complete Blood Count in a few minutes.
Customers
Sight Diagnostics® Expands to the Gulf Region through a Distribution Partnership with Phoenix Capital
growth-positive
MedCity Pivot Podcast: Sight Diagnostics' exec talks about using computer vision in blood diagnostics
Israeli startup Sight Diagnostics, which aims to transform the world of blood diagnostics, has raised over $120 million and received FDA approval for its Olo device. In an interview, Daniel Levner, co-founder and chairman of the companys scientific advisory board, discusses the product and the potential of computer vision and AI in blood diagnostics.
Investment
growth-positive
https://www.jpost.com/health-science/sight-diagnostics-shaare-zedek-sign-coronavirus-research-collaboration-648870
Shaare Zedek Medical Center and Sight Diagnostics will collaborate on a study to examine morphological changes in white blood cells of coronavirus patients. The study aims to detect early deterioration of patients health status. The collaboration agreement reflects a long-standing partnership between the medical center and Sight. The research will utilize Sights flagship device, the Sight OLO, which combines artificial intelligence and image processing technology for blood diagnostics. The partnership will leverage Shaare Zedeks large biobank and Sights advanced device capabilities to identify deterioration processes in coronavirus patients and enable accurate and rapid treatment. The collaboration is expected to have a positive impact on the growth of Shaare Zedek Medical Center.
PartnersCustomers
growth-positive
Blood count device co Sight Diagnostics raises $71m
Israeli rapid blood diagnostics developer Sight Diagnostics has raised $71 million in a financing round led by US corporations and international venture capital funds. The company has developed a blood count device that is approved by the US Food and Drug Administration (FDA) and WHO. The device provides swift results and is compact and easy to use. It is not specifically a test for coronavirus, but it is important for all patients with fever and those with a diagnosis to monitor their condition. The financing round has resulted in Clal Biotechnology Industries holding a 4% stake in Sight Diagnostics.
Investment
growth-positive
Blood testing startup partners with Israel's Sheba Medical Center to support COVID-19 quarantine measures
Israeli blood testing startup Sight Diagnostics has collaborated with Sheba Medical Center to use its OLO blood analyzer for rapid complete blood count (CBC) testing of COVID-19 patients. The OLO analyzer provides CBC results in minutes using a self-contained cartridge that collects two drops of blood. The collaboration aims to mitigate the risk of contamination by processing samples in a separate field hospital. Sight Diagnostics previously raised $27.8 million in Series C funding. Sheba Medical Center has been using telehealth solutions to treat and monitor coronavirus-exposed patients.
PartnersCustomers
growth-positive
CTalk: This Startup Develops Painless Blood Tests
Yossi Pollak, CEO of Sight Diagnostics, spoke about the need for more accessible blood tests at the OurCrowd Summit in Jerusalem. Sight Diagnostics develops machine vision-based technology for blood test analysis and infectious disease diagnosis. Their products include the malaria detection system Parasight and the blood count device OLO.
CustomersPartners
growth-positive
Dubbed 'Anti-Theranos,' An Israeli Startup Is Delivering On Blood Test Device With Results In Minutes
Israeli tech firm Sight Diagnostics has received initial clearance from the US FDA for its lab-grade blood testing system that can conduct a full blood analysis with just a few drops of blood. The companys technology has been compared to that of Theranos, the American biotech firm that faced fraud charges. Sight Diagnostics has been praised for its accurate blood test results from a small amount of blood. The companys OLO blood testing analyzer has been granted FDA clearance and can be used in laboratories run by hospitals, diagnostic providers, and outpatient clinics. Sight Diagnostics aims to expand its offering in the future and improve patient outcomes through faster, less costly, and more convenient testing.
Customers
growth-positive
Blood Diagnostics Firm Sight Gets FDA Nod For Device That Delivers Results In Minutes
Sight Diagnostics has received FDA clearance for its OLO analyzer, a device that performs blood tests and provides lab-grade results in minutes. The analyzer leverages AI to digitize blood and allows patients to receive results with just a finger-prick. The FDA clearance enables OLOs use in laboratories run by hospitals, diagnostic providers, and outpatient clinics. Sight Diagnostics plans to pursue further FDA approval to certify OLO for use in smaller medical practices and pharmacies in the United States. The company has also initiated a pilot program with UK pharmacy chain Superdrug. Sight Diagnostics was founded in 2011 and has six patents with more pending.
CustomersPartnersInvestmentExpand
growth-positive
Startup's 10-minute blood test device shifts focus from lab to doctor's clinic
Israeli startup Sight Diagnostics has developed a medical device called OLO that allows for faster blood testing at the point of care. The device can provide results of a standard blood count test in 10 minutes, eliminating the need to send samples to a lab. OLO is cost-effective and can be placed on every doctors desk. Sight Diagnostics has already launched its first product, Parasight, for detecting malaria. The companys second-generation product, OLO, performs a complete blood count and has been approved for sale in the EU. Sight Diagnostics has applied for FDA clearance and is studying ways to expand its platform to include other diagnostic capabilities. The company has raised $55 million from investors and is growing.
CustomersPartnersInvestment
growth-positive
Sight Diagnostics successful in clinical trial
Sight Diagnostics, a company that has developed a real-time blood test requiring only a few drops of blood, has completed a successful clinical trial for its device. The company believes that the trial results are enough to submit a request for FDA marketing approval. The product is already being marketed in Europe and Israel. Sight Diagnostics raised $28 million last December.
Investment
growth-positive
Sight Diagnostics Named To Fast Company's Annual List Of The World's Most Innovative Companies for 2019
Sight Diagnostics has been named the most innovative company in the Middle East by Fast Company. The company has developed an AI-based blood diagnostics platform called OLO, which provides lab-quality Complete Blood Count (CBC) tests and delivers results within minutes at the point-of-care. Sight Diagnostics recently announced a $27.8 million Series C funding round led by Longliv Ventures, which will be used to continue the global commercialization of OLO and expand its menu of diagnostic tests. The companys innovative approach to blood testing has the potential to transform healthcare by providing accurate and convenient diagnostic testing in a shorter timeframe.
Customers
growth-positive
Biotech AI startup Sight Diagnostics gets $27.8M to speed up blood tests
Israeli medical devices startup Sight Diagnostics has closed a $27.8 million Series C funding round. The funding will be used to sell its OLO blood diagnostics system, expand into major markets worldwide, and support regulatory efforts in the US. Strategic investors include Longliv Ventures, CK Hutchison Group, Jack Nicklaus II, Steven Esrick, and a major medical equipment manufacturer. Sight Diagnostics is seeking additional strategic partners to help with global deployment. The company expects customers in multiple European countries to deploy OLO this year. The funding will also go towards R&D to expand the menu of diagnostic tests offered by OLO.
InvestmentExpand
growth-positive
Sight Diagnostics uses computer vision to analyze blood samples
Sight Diagnostics, a medical company based in Tel Aviv, has developed a desktop machine called Olo that can analyze blood from single-use cartridges. Olo uses artificial intelligence (AI) to process scans and can conduct lab-grade complete blood count (CBC) tests in 10 minutes. The device has completed a clinical trial and received a CE Mark registration from the European Union. It is currently undergoing clinical trials in the US and aims to obtain FDA approval in 2019. Sight Diagnostics has raised $25 million in funding from Innovation Endeavors. The company is also considering the possibility of a cloud service for remote scans in the future.
InvestmentExpand
growth-positive
Sight Diagnostics starts selling an AI-based diagnostics device for faster blood tests
Israeli medical devices startup Sight Diagnostics has launched a point-of-care blood diagnostics system called OLO. The compact machine uses computer vision and machine learning technology to analyse single-use cartridges loaded with drops of blood, delivering lab-grade complete blood count (CBC) tests from a finger prick of blood. Sight Diagnostics has raised $25m in equity financing from VC firms, including Eric Schmidt’s Innovation Endeavors, and is in the process of raising a Series C. The company aims to offer a high-tech alternative to traditional blood testing methods, providing faster and more convenient diagnostics for medical conditions. OLO has completed a clinical trial and obtained CE Mark registration for commercial sale in Europe. The company is also conducting FDA testing in the US.
Investment
growth-positive
DCL, Sight Diagnostics introduce automated malaria detection device
DCL Laboratory Product Limited has collaborated with Sight Diagnostics Limited to introduce the Parasight Malaria Detection Platform in Nigeria and Ghana. The collaboration aims to advance the world of health by bringing technology solutions for malaria diagnosis to West Africa. The Parasight Platform uses computer vision technology to analyze blood samples for malarial parasites, providing a diagnostic result within four minutes. The platform has undergone successful field-testing and demonstrated high sensitivity and specificity. The introduction of this innovative machine is expected to make malaria diagnosis easier and eliminate the inaccuracy of diagnosis in Nigeria.
Customers
growth-positive
Medic West Africa- PRESS RELEASES
DCL Laboratory Product Ltd has announced a collaboration with Sight Diagnostics Ltd to introduce the Parasight Malaria Detection Platform in Nigeria and Ghana. This collaboration will introduce the first automated malaria diagnostics equipment in Nigeria and Ghana. The Parasight Malaria Detection Platform uses computer vision technology to analyze blood samples for malarial parasites and provides a diagnostic result within four minutes. The platform has undergone successful field testing in Nigeria and has been sold to healthcare providers in 18 countries. DCL Laboratory Product Ltd is a leading provider of medical laboratory solutions in West Africa.
Customers
growth-positive
Fast, accurate test for malaria could be a game-changer
Israeli company Sight Diagnostics has developed a device that uses computer vision-based algorithms to detect malaria rapidly and accurately. The device, called Parasight, completes malaria tests in less than four minutes with over 99% accuracy. It also identifies the malaria species and counts the number of parasites per microliter. Sight Diagnostics recently completed a $15 million funding round led by Chinese-Israeli VC Go Capital. The company plans to expand its diagnostic platform to include a portable point-of-care version and a complete blood count (CBC) device. The CBC device will be tested in Kenya and is expected to address the challenge of finding individuals who are infected with malaria but show no symptoms.
Customers
growth-positive
Sight Diagnostics Ltd. and the United States Army Announce a Joint Collaboration
Sight Diagnostics has announced a collaboration with the United States Army Medical Research Directorate Kenya (USAMRD-K) to develop and test the next generation of their malaria diagnostic technology. They will be developing a portable malaria and complete blood count (CBC) reader that will be tested in clinical trials in Kenya. The collaboration with USAMRD-K recognizes Sight Diagnostics success in bringing their high-throughput computer vision malaria diagnostic technology to the market. The company aims to launch a point of care version of the platform in remote locations and austere environments. The project will be conducted in collaboration with Dr. John Waitumbi, senior scientist and chief of the Basic Science Laboratory at USAMRD-K. The portable version of the malaria diagnostic technology will provide additional diagnostic information critical to healthcare providers in remote areas.
Partners
growth-positive
Israel's SightDx Detects Malaria In Blood In Only Three Minutes
Israeli startup Sight Diagnostics has developed a medical breakthrough that uses computer vision technology to detect blood-borne diseases such as malaria. The companys algorithms visually scan and analyze blood samples, providing results in just three minutes compared to the one or two days it takes for traditional lab results. Sight Diagnostics has achieved 99% accuracy in sensitivity and 98% accuracy in specificity in pilot tests. The company has already fulfilled orders for 20 malaria-detecting devices and is developing a complete blood count test for release next year. Sight Diagnostics has raised $6 million in funding from OurCrowd, Clal Bio, and Innovation Endeavors.
CustomersInvestment
Sight Diagnostics Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 69 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Sight Diagnostics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514496280 |
| Crunchbase | sight-diagnostics |
| Creator | Sharon Shapira |
| Creator email | shapira.sharon2@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-11T00:00:00.000Z |
| Created | 2014-11-06T00:00:00.000Z |